ZIRCON-X was designed as a post-hoc analysis of imaging data collected in the ZIRCON trial to evaluate how the incorporation of 89 Zr-girentuximab PET imaging could influence clinical management ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Positron emission tomography (PET) is an imaging modality to better understand the pathophysiology of a disease at molecular level and typically referred to as molecular imaging. It reveals the ...

Professor of Medical Imaging at the University of Arizona Lars Furenlid, the project’s lead researcher. Professor of Radiology at UMass Chan Medical School Michael King. In order to better study and ...

PET scans may serve as both a diagnostic and prognostic tool in giant cell arteritis (GCA), according to a new study. In over 100 patients with GCA who underwent 18 F-fluorodeoxyglucose (FDG) PET ...

The Centers for Medicare & Medicaid Services (CMS) has expanded coverage of brain amyloid positron-emission tomography (PET) imaging for the diagnosis of Alzheimer's disease (AD). The CMS decision, ...